We have known for many years that autoimmune diseases such as rheumatic fever and Guillain-Barré syndrome (where the body makes antibodies that attack the heart and peripheral nerves respectively) can occur after the body makes immune responses against certain infectious micro-organisms.
We have not been able to explain exactly how such examples of infection-driven autoimmunity occur, however, nor why our bodies seem unable to prevent them.
Our immune cells, such as the antibody-creating B cells, go through processes when they are first formed that ensure they are able to identify our own bodies, and therefore avoid self-attack. These processes are generally reliable as they take place in a steady, regulated way.
B cells go through a second and much more chaotic phase of development, however, when the body is fending off disease or infection. In order to cope with the immeasurable range of microbes in our environment, B cells have evolved the ability to mutate their antibody genes randomly until they produce one that sticks strongly to the invader. At that point, the ‘successful’ B cells proliferate and flood the system with these new antibodies.
This ‘high affinity antibody’ generation occurs very rapidly within specialised environments in the lymph system known as ‘germinal centres’. Most of the time, germinal centres serve us well, helping us fight disease and build up a protective armory for the future.
Unfortunately, the urgency and speed at which B cells mutate within the germinal centre, as well as the random nature of the process, creates a unique problem. Sometimes the antibody created to fight the invader, or ‘antigen’, also happens to match ‘self’ and has the potential to cause autoimmune attack.
Dr Tyani Chan and Associate Professor Robert Brink from Sydney’s Garvan Institute of Medical Research developed sophisticated mouse models to investigate when and how this happens. They demonstrated that when antigen is abundant and generally available throughout the body, rogue autoantibody-generating B cells are deleted and autoimmunity avoided. Conversely, when target antigen is located only in a tissue or organ remote from the germinal centre, B cells capable of reacting against both antigen and ‘self’ are able to escape the germinal centre and produce autoantibodies. Their finding is published in the prestigious international journal Immunity.
“Essentially we’ve shown there’s a big hole in self-tolerance when it comes to cross-reactive autoantibodies that can attack organ-specific targets,” said Brink.
“Our finding explains a lot about how autoimmune conditions that target particular organs such as the heart or nervous system could develop after an infection. It also suggests that if you know enough about the disease and the molecular messaging systems involved, it may be possible in future to modulate the germinal centre response.”
The team will continue to use their new mouse model to study the various molecular reactions involved in the progression of an autoimmune response.
The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent’s Hospital in Sydney, it is now one of Australia’s largest medical research institutions with over 600 scientists, students and support staff. Garvan’s main research programs are: Cancer, Diabetes & Obesity, Immunology and Inflammation, Osteoporosis and Bone Biology and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.
All media enquiries should be directed to:
Science Communications Manager
M: + 61 434 071 326
P: +61 2 9295 8128
E: a.heather “a” garvan.org.au